Product Pipeline - Zumutor Biologics

Immuno-oncology targets

TARGET	DISEASE INDICATIONS	STATUS – KEY DATA	MILESTONE
ZM008 Lead Molecule New target. Functions through NK cell based therapy	Prostate Cancer, B cell lymphoma, glioma, rheumatoid arthritis	Strong in vivo efficacy Ongoing clinical risk mitigation studies Development management team in place	IND filing in Q2 2020
ZM012 mAb target. Functions through tumour associated antigen/NK cell receptor	Lymphoma and other Undisclosed indications	Unique Clone identification in process	Target identity in Q4 2019
ZM014 mAb target. Functions through tumour NK cell receptor	Lymphoma	Unique Clone identification in process	Target identity in Q4 2019

TARGET

DISEASE INDICATIONS

STATUS – KEY DATA

MILESTONE

ZM008

Lead Molecule
New target. Functions through NK cell based therapy

Prostate Cancer,
B cell lymphoma, glioma, rheumatoid arthritis

IND filing in
Q2 2020

ZM012

mAb target. Functions through tumour associated antigen/NK cell receptor

Lymphoma and other Undisclosed indications

Unique Clone identification in process

Target identity in Q4 2019

ZM014

mAb target. Functions through tumour NK cell receptor

Lymphoma

Unique Clone identification in process

Target identity in
Q4 2019

Molecules for NK cell and cell targets under development

Future targets of interest

In vivo efficacy study completed

Selection of Ab producing stable cell lines.
Process development large scale manufacture

Stability studies,

CMC Package Development